Navigation Links
Mylan Announces Extension of Tender Offers for Its 5.750% Senior Notes due 2010 and 6.375% Senior Notes due 2015
Date:9/28/2007

PITTSBURGH, Sept. 28 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) ("Mylan") announced today that it has extended the expiration time of each of its previously announced cash tender offers and consent solicitations for its 5.750% Senior Notes due 2010 (CUSIP No. 628530AE7) (the "2010 Notes") and 6.375% Senior Notes due 2015 (CUSIP Nos. 628530AF4, 628530AC1) (the "2015 Notes" and, together with the 2010 Notes, the "Notes"), which are being conducted pursuant to the terms and subject to the conditions described in the Offer to Purchase and Consent Solicitation Statement and related Letter of Instructions dated August 31, 2007 (collectively, the "Offer to Purchase"). As a result of the extensions, each of the tender offers will now expire at 10:00 a.m., New York City time, on October 2, 2007, unless Mylan chooses to again extend or to terminate any tender offer as provided in the Offer to Purchase.

As previously announced, Mylan is making the tender offers in connection with the consummation of its proposed acquisition of Merck's generic pharmaceutical business pursuant to a Share Purchase Agreement, dated May 12, 2007, between Mylan and Merck Generics Holding GmbH, Merck S.A., Merck Internationale Beteiligung GmbH and Merck KGaA (the "Transaction"), and certain financing arrangements being entered into to fund such acquisition. The extensions have been made because the closing of the Transaction, which is a condition to the tender offers, is now expected to occur on October 2, 2007.

As of 5:00 p.m., New York City time, on September 27, 2007, Mylan had received tenders of Notes and deliveries of related consents for approximately $147.5 million in aggregate principal amount of the 2010 Notes, representing 98.31% of the outstanding 2010 Notes, and $349.8 million in aggregate principal amount of the 2015 Notes, representing 99.94% of the outstanding 2015 Notes. Notes tendered may not be withdrawn, and consents given may not be revoked, unless the applicable tender offer is terminated without any Notes being purchased.

Mylan's obligation to accept, and pay for, Notes of a series validly tendered pursuant to a tender offer is conditioned upon the satisfaction or waiver of various conditions, including consummation of the Transaction and certain general conditions described in the Offer to Purchase.

The complete terms and conditions of the tender offers and consent solicitations are described in the Offer to Purchase, copies of which may be obtained by contacting Global Bondholder Services Corporation, the information agent for the tender offers and consent solicitations, at (866) 804-2200 (toll-free). Questions regarding the tender offers and consent solicitations may be directed to the Dealer Managers and Solicitation Agents for the tender offers and consent solicitations, Merrill Lynch, Pierce, Fenner & Smith Incorporated, which may be contacted at (212) 449-4914 (collect) or (888) 654- 8637 (toll-free), and Citigroup Global Markets Inc., which may be contacted at (212) 723-6106 (collect) or (800) 558-3745 (toll-free).

This announcement is not an offer to purchase, a solicitation of an offer to purchase or a solicitation of consents with respect to any securities. The tender offers and consent solicitations are being made solely by Mylan's Offer to Purchase, as the same may be amended or supplemented by Mylan.


'/>"/>
SOURCE Mylan Laboratories Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Wins Its Amlodipine Case With Pfizer
2. Mylan Announces Tentative FDA Approval for Its ANDA
3. Mylan Announces Final FDA Approval for Fluoxetine Capsules
4. PM announces a new health care order for India
5. Ramdoss Announces Introduction of RCH-II
6. Britain Announces Third Transfusion Related Mad Cow Case
7. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
8. Tibet Announces the Dalai Lama’s Tour of South Americ
9. NHS announces further Cost cutting Measures
10. Indian PM Announces Of Setting Up India Study Center At Tashkent
11. PowderMed Announces Needle-Less Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... Vancouver, British Columbia (PRWEB) , ... June 28, ... ... (OTCQB: CNZCF) (FSE: ZEON) is pleased to announce that a two year study ... using the Company's Bromley Creek zeolite was successful in remediating potash brine-impacted groundwater. ...
(Date:6/28/2017)... , ... June 28, 2017 , ... ... firm servicing communities throughout the greater Cincinnati metropolitan area, is teaming up with ... lodgings for families with children receiving treatment in nearby hospitals. , Ronald McDonald ...
(Date:6/27/2017)... Zurich, Switzerland (PRWEB) , ... June 27, 2017 , ... ... crowd to manage token assets on the Ethereum blockchain, has released their technical ... but until now, there has been little systematic approach for determining which offerings will ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... From June ... The three-day event was held in Syracuse, New York, where EarQ is headquartered. , ... industry, how to connect with today’s savvy consumer, and the latest in hearing ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... to an upcoming case studies guidebook. This guidebook offers an excellent branding and ... will include articles, case studies and how-to’s that fall into the following categories:, ...
Breaking Medicine News(10 mins):
(Date:6/11/2017)... INDIANAPOLIS , June 10, 2017  Eli Lilly and ... results from three Phase 3 studies of galcanezumab, an ... migraine, including late-breaking data on several key secondary endpoints ... Detailed results from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) ... (AHS) annual scientific meeting in Boston ...
(Date:6/9/2017)... INDIANAPOLIS , June 9, 2017 ... In a further effort to help spread lessons learned ... condition, the International Diabetes Federation (IDF) and Eli Lilly ... together for the second phase of the Bringing Research ... 2), reaffirming their commitment to helping people with diabetes ...
(Date:6/8/2017)... , June 8, 2017  StatLab Medical ... developer and manufacturer of diagnostic supplies for ... that Cressey & Company LP ("Cressey & ... completed a growth-focused investment in the Company. ... ownership position from selling shareholder, Prairie Capital, ...
Breaking Medicine Technology: